8/14/2019 1-Indias Pharmaceuticals Industry
1/61
Indias PharmaceuticalsIndustry
The Indian pharmaceutical industry isa success story providing employmentfor millions and ensuring that essentialdrugs at affordable prices are available
to the vast population of this sub-continent.
Richard Gerster
8/14/2019 1-Indias Pharmaceuticals Industry
2/61
8/14/2019 1-Indias Pharmaceuticals Industry
3/61
8/14/2019 1-Indias Pharmaceuticals Industry
4/61
8/14/2019 1-Indias Pharmaceuticals Industry
5/61
8/14/2019 1-Indias Pharmaceuticals Industry
6/61
8/14/2019 1-Indias Pharmaceuticals Industry
7/61
The Indian pharmaceuticalsector has come a long way,being almost non-existentbefore 1970 to a prominent
provider of healthcareproducts, meeting almost 95per cent of the country'spharmaceuticals needs.
8/14/2019 1-Indias Pharmaceuticals Industry
8/61
The Industry today is in the front rank ofIndias science -based industries with
wide ranging capabilities in the complexfield of drug manufacture andtechnology.
It ranks very high in the third world, interms of technology, quality and range ofmedicines manufactured.
From simple headache pills tosophisticated antibiotics and complexcardiac compounds, almost every type ofmedicine is now made indigenously.
8/14/2019 1-Indias Pharmaceuticals Industry
9/61
Playing a key role in promoting
and sustaining development in thevital field of medicines, Indian Pharma Industry boasts
of quality producers and manyunits approved by regulatory
authorities in USA and UK.
8/14/2019 1-Indias Pharmaceuticals Industry
10/61
International companies
associated with this sectorhave stimulated, assisted andspearheaded this dynamicdevelopment in the past 53years and helped to put India
on the pharmaceutical map ofthe world.
8/14/2019 1-Indias Pharmaceuticals Industry
11/61
The Indian Pharmaceutical
sector is highly fragmentedwith more than 20,000registered units with severeprice competition andgovernment price control. It
has expanded drastically inthe last two decades.
8/14/2019 1-Indias Pharmaceuticals Industry
12/61
There are about 250 large units that control 70per cent of the market with market leaderholding nearly 7 per cent of the market shareand about 8000 Small Scale Units togetherwhich form the core of the pharmaceuticalindustry in India (including 5 Central PublicSector Units). These units produce the completerange of pharmaceutical formulations, i.e.,medicines ready for consumption by patients
and about 350 bulk drugs, i.e., chemicals havingtherapeutic value and used for production ofpharmaceutical formulations.
8/14/2019 1-Indias Pharmaceuticals Industry
13/61
Following the de-licensing of the pharmaceuticalindustry, industrial licensing for most of the
drugs and pharmaceutical products has beendone away with. Manufacturers are free toproduce any drug duly approved by the DrugControl Authority. Technologically strong and
totally self-reliant, the pharmaceutical industry inIndia has low costs of production, low R&Dcosts, innovative scientific manpower, strengthof national laboratories and an increasingbalance of trade.
8/14/2019 1-Indias Pharmaceuticals Industry
14/61
The total Indian productionconstitutes about 13 per cent of theworld market in value terms and, 8per cent in volume terms.
The per capita consumption of drugsin India, stands at US$3, is amongstthe lowest in the world, as compared
to Japan- US$412, Germany-US$222 and USA- US$191.
8/14/2019 1-Indias Pharmaceuticals Industry
15/61
India's US$ 9.4 billion pharmaceuticalindustry is growing at the rate of 14percent per year.
It is one of the largest and mostadvanced among the developingcountries.
The Indian pharmaceutical industry
can reach a market size of US$ 11.6billion by 2009.
8/14/2019 1-Indias Pharmaceuticals Industry
16/61
8/14/2019 1-Indias Pharmaceuticals Industry
17/61
8/14/2019 1-Indias Pharmaceuticals Industry
18/61
There are 74 U.S. FDA-approvedmanufacturing facilities in India,more than in any other countryoutside the U.S, and in 2005,almost 20 per cent of all
Abbreviated New Drug Applications (ANDA) to the FDAwere filed by Indian companies.
8/14/2019 1-Indias Pharmaceuticals Industry
19/61
Growth in other fieldsnotwithstanding, generics are stilla large part of the picture.
London research company Global
Insight estimates that Indiasshare of the global genericsmarket will have risen from 4 percent to 33 per cent by 2007.
8/14/2019 1-Indias Pharmaceuticals Industry
20/61
The Changing Prescription
As per WTO, from the year 2005, Indiagranted product patent recognition to allnew chemical entities (NCEs) i.e., bulk
drugs developed then onwards. This introduction of product patent regime
from January 2005 is leading into long-term growth for the future which mandatedpatent protection on both products andprocesses for a period of 20 years.
8/14/2019 1-Indias Pharmaceuticals Industry
21/61
Under this new law, India will be
forced to recognize not only newpatents but also any patents filedafter January 1, 1995. Under
changed environment, the industryis being forced to adapt itsbusiness model to recent changesin the operating environment.
8/14/2019 1-Indias Pharmaceuticals Industry
22/61
8/14/2019 1-Indias Pharmaceuticals Industry
23/61
The Indian Government's decision toallow 100 percent foreign direct
investment into the drugs andpharmaceutical industry is expected to aidthe growth of contract research in thecountry.
MNCs in India is facing the problem ofhaving a very high Drugs Price ControlOrder (DPCO) coverage, weakening their
bottom lines as well as hindering theirgrowth through the launch of newproducts. DPCO coverage is expected tobe diluted further in the near futurebenefiting the MNCs.
8/14/2019 1-Indias Pharmaceuticals Industry
24/61
8/14/2019 1-Indias Pharmaceuticals Industry
25/61
Emerging Trend Global pharma cos expected to launch 200-250
new drugs over next 8-10 years totaling anestimated US$ 3-5 billion
FDI inflow grew over six fold from US$ 60.7 mnin 2003 to US$ 340 mn, in fiscal year 2004 Bristol Myers Squibb, Boehringer Ingelheim and
Eisai without Indian presence earlier, have made
recent foray Indian firms tying up with foreign companies toin-license drugs
8/14/2019 1-Indias Pharmaceuticals Industry
26/61
Res earch & Develo p m en t
8/14/2019 1-Indias Pharmaceuticals Industry
27/61
8/14/2019 1-Indias Pharmaceuticals Industry
28/61
8/14/2019 1-Indias Pharmaceuticals Industry
29/61
8/14/2019 1-Indias Pharmaceuticals Industry
30/61
8/14/2019 1-Indias Pharmaceuticals Industry
31/61
8/14/2019 1-Indias Pharmaceuticals Industry
32/61
Domestic Demand
The growing population of over of a billion Increasing income
Demand for quality healthcare service Changing lifestyle has led to change indisease patterns, and increased demandfor new medicines to combat lifestylerelated diseases
8/14/2019 1-Indias Pharmaceuticals Industry
33/61
8/14/2019 1-Indias Pharmaceuticals Industry
34/61
Exports
Over 60 per cent of Indias bulk drugproduction is exported. Indiaspharmaceutical exports are to thetune of Rs87 billion, of whichformulations contribute nearly 55 percent and the rest 45 per cent comesfrom bulk drugs.
In financial year 2005, exports grewby 21 per cent.
8/14/2019 1-Indias Pharmaceuticals Industry
35/61
The Indian pharmaceutical market has
been forecasted to grow to as much asUS$ 25 billion by 2010 as per Organizationof Pharmaceutical Producers of India(OPPI) estimates.
However, Espicoms market projectionsforecast more modest but stable annualmarket growth of around 7.2 per cent,putting the market at US$ 11.6 billion by2009.
8/14/2019 1-Indias Pharmaceuticals Industry
36/61
8/14/2019 1-Indias Pharmaceuticals Industry
37/61
8/14/2019 1-Indias Pharmaceuticals Industry
38/61
Domestic pharmaceutical exports, growing at 30per cent per annum, touched a new height ofUS$4.8 billion in the financial year 2006-07. TheYears exports will push the drug sectorscontribution to Indias Forx earnings to 7.75 percent from the current 5 per cent.
The growth in drug exports, despite the pressinggeneric competition in the global markets, isattributed to increased Abbreviated New Drug
Applications (ANDAs) approvals in the USmarket and contribution from unconventional
markets in Latin America, Australia and theemerging markets in the Middle East and African Region.
8/14/2019 1-Indias Pharmaceuticals Industry
39/61
The export revenue nowcontributes almost half of the totalrevenue for the top three
pharmaceutical majors: DrReddys, Ranbaxy and Cipla.
8/14/2019 1-Indias Pharmaceuticals Industry
40/61
The other major exporters areWockhardt Limited, SunPharmaceutical Industries Ltd. andLupin Laboratories. The formulationsand exports are largely to developingnations in CIS, South East Asia,
Africa and Latin America .
8/14/2019 1-Indias Pharmaceuticals Industry
41/61
OTC The Indian market for over-the-counter
medicines (OTCs) is worth about $940million and is growing 20 percent a year, ordouble the rate for prescription medicines.
The industry's exports were worth morethan $3.75 billion in 2004-05 and they havebeen growing at a compound annual rateof 22.7 percent over the last few years,according to the government's draftNational Pharmaceuticals Policy for 2006,published in January 2006.
8/14/2019 1-Indias Pharmaceuticals Industry
42/61
8/14/2019 1-Indias Pharmaceuticals Industry
43/61
8/14/2019 1-Indias Pharmaceuticals Industry
44/61
Import
8/14/2019 1-Indias Pharmaceuticals Industry
45/61
8/14/2019 1-Indias Pharmaceuticals Industry
46/61
The government should implement the
recommendations of Mashelkar committeeand constitute the Central Drug Authorityat the earliest.
The basic course of education should bedesigned to ensure that the newly qualifiedpharmacist has the necessary knowledgeand skills to commence practicingcompetently in a variety of settingsincluding community and hospitalpharmacy and the pharmaceutical industry.
8/14/2019 1-Indias Pharmaceuticals Industry
47/61
8/14/2019 1-Indias Pharmaceuticals Industry
48/61
The pharmacy profession will makethe clinical trial industry in India to
grow to over a billion dollars in thenext five years and position itself as adestination of choice for CRO
services by way of strictimplementation of patent laws, singlewindow clearance of clinical trialprotocols by regulatory clearancesand shall accord industry status tothis sector.
8/14/2019 1-Indias Pharmaceuticals Industry
49/61
India will emerge as a major global playerin the field of pharmaceuticals exports and
as a provider of quality medicines at lowcosts. It shall also emerge as a majorplayer in the generic drugs market in USAand Europe.
India shall attain new heights in herbaldrugs research in shaping Indian Systemsof Medicine into a popular system ofmedicine of the future for holistic healthcare and ensuring health care for all -especially for the welfare of the poor.
8/14/2019 1-Indias Pharmaceuticals Industry
50/61
Indias Patents Act should ensure that itdoes not exceed the requirements ofTRIPS, and that prioritizes access tomedicines and public health, whileretaining the right to participate in thecompulsory license scenario.
India should lead a movement ofdeveloping nations and create a TRIPS
south and G-20 alliance is a step in thatdirection
8/14/2019 1-Indias Pharmaceuticals Industry
51/61
8/14/2019 1-Indias Pharmaceuticals Industry
52/61
8/14/2019 1-Indias Pharmaceuticals Industry
53/61
8/14/2019 1-Indias Pharmaceuticals Industry
54/61
Challenges
Und erdevelop ed new m oleculed isco very prog ram Hue & cry agains t exploi ta t ion
Back l ash aga ins t ou t sourc in g
IP leakag e
Restr ic ted i tems
Reservat ion for s m al l sca le indus t r ies
No brand va lue
Gener ic com pet i t ion
8/14/2019 1-Indias Pharmaceuticals Industry
55/61
Opportunities A few important strengths are mentioned below.
Com petent wo rkforc e India has a pool of personnelwith high managerial and technical competence asskilled workforce. It has the largest English speakingpopulation in the world. Professional services are easilyavailable.
Cost-effect ive Chem ical Syn thesis Its track record ofdevelopment, particularly in the area of improved cost-beneficial chemical synthesis for various drug molecules
is excellent. It provides a wide variety of bulk drugs andexports sophisticated bulk drugs. Legal & Financial Framewo rk
8/14/2019 1-Indias Pharmaceuticals Industry
56/61
Inform at ion & Tech no logy Global iza t ion
Conso l ida t ion
L o w p r i c ed p r o d u c t s Qual i ty assuranc e
Dominance in the marke t
Self-rel iance
Low cost of production, Low R&D costs, Innovative Scientific manpower
8/14/2019 1-Indias Pharmaceuticals Industry
57/61
8/14/2019 1-Indias Pharmaceuticals Industry
58/61
8/14/2019 1-Indias Pharmaceuticals Industry
59/61
8/14/2019 1-Indias Pharmaceuticals Industry
60/61
8/14/2019 1-Indias Pharmaceuticals Industry
61/61
THANK YOU